Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Kaiser Permanente |
---|---|
Information provided by: | Kaiser Permanente |
ClinicalTrials.gov Identifier: | NCT00312117 |
Contrast nephropathy (CN) is a common cause of renal failure associated with prolonged hospitalization, significant morbidity/mortality, and cost. In addition, these patients may require temporary or permanent hemodialysis which, in turn, is associated with further morbidity, mortality, and cost. CN has been reported to account for 10% of hospital acquired renal failure. In recent years, studies have investigated preventive therapies with mixed results. Fenoldopam was found to be ineffective in a large randomized trial. Dopamine has been shown to be ineffective as a preventive strategy. Hemofiltration has been shown to be beneficial (New England Journal of Medicine [NEJM] 2003) but is costly and not practical. Mucomyst has shown mixed results. The single strategy which most would agree as being beneficial remains hydration, most commonly with intravenous 0.9% normal saline. Most recently, sodium bicarbonate has been shown to be beneficial in a small randomized trial (n=119). It is clear that the most cost effective strategies for treatment of CN should be aimed at prevention.
The general question is: "Is a sodium bicarbonate solution more efficacious in preventing contrast nephropathy compared to normal saline?" The general hypothesis is that sodium bicarbonate will be more efficacious.
Condition | Intervention | Phase |
---|---|---|
Contrast Induced Nephropathy Kidney Diseases |
Drug: Sodium bicarbonate |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate |
Estimated Enrollment: | 300 |
Study Start Date: | January 2006 |
Study Completion Date: | February 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Kaiser Permanente Medical Center | |
Los Angeles, California, United States, 90027 |
Principal Investigator: | Somjot S Brar, M.D. | Kaiser Permanente Southern California |
Study ID Numbers: | 4353 |
Study First Received: | April 5, 2006 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00312117 |
Health Authority: | United States: Institutional Review Board |
contrast induced nephropathy sodium bicarbonate cardiac catheterization |
Urologic Diseases Kidney Diseases |